SCHEMBL2901224

SCHEMBL2901224

CCC=C(C(=O)O)C(=O)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CES2 O00748 13/20 0.52
CES1 P23141 12/20 0.52
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HIF1A Q16665 1/20 0.42
MAPT P10636 3/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 2/20 0.41
EGFR P00533 1/20 0.41
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
RAB9A P51151 1/20 0.40
XBP1 P17861 1/20 0.40
ATM Q13315 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10393740 1.00 CES2 (0.52) CES2CES1CYP1A2CYP3A4CYP2C9
SCHEMBL16973952 0.85 CES2 (0.52) CES2CES1MAPTALDH1A1LMNA
SCHEMBL995359 0.81 MAPT (0.59) CES2CES1CYP1A2CYP2C9CYP2C19
SCHEMBL11723691 0.81 MAPT (0.59) CES2CES1CYP1A2CYP2C9CYP2C19
SCHEMBL27662613 0.80 CES2 (0.43) CES2CES1CYP1A2CYP3A4CYP2C9
Ammonia Solution, Strong SCHEMBL28224094 0.80 EP300 (0.59) CES2CES1CYP1A2CYP3A4CYP2C9
SCHEMBL7451708 0.80 EP300 (0.64) CES2CES1
SCHEMBL11560694 0.80 EP300 (0.64) CES2CES1
SCHEMBL16974008 0.80 CES2 (0.61) CES2CES1MAPTALDH1A1KMT2A
SCHEMBL9540488 0.79 CES2 (0.56) CES2CES1CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106192061-A A kind of anophelifuge PBAT fiber 福建经纬新纤科技实业有限公司 2016-12-07 CN claimed
US-4925969-A MICHAEL ADDITION, ALANINE OR LYSINE DERIVATIVE REACTED WITH ETHYL BENZOYLACRYLATE KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1990-05-15 US claimed
EP-0190687-B1 PROCESS FOR PREPARING ETHYL-ALPHA-(1-CARBOXYETHYL)-AMINO-GAMMA-OXO-GAMMA-PHENYLBUTYRATE KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1988-10-05 EP claimed
EP-0190687-A1 Process for preparing ethyl-alpha-(1-carboxyethyl)-amino-gamma-oxo-gamma-phenylbutyrate KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1986-08-13 EP claimed
CN-114369198-B 3-benzoyl ethyl acrylate diesel pour point depressant, diesel pour point depressant composition, preparation and application 上海应用技术大学 2023-03-31 CN disclosed
CN-114933543-A Synthetic method of 3-cyclopropylamino-2- (2, 4-dichloro-5-fluorobenzoyl) methyl acrylate 山东国邦药业有限公司 2022-08-23 CN disclosed
CN-114605587-A PMA diesel pour point depressant and preparation method and application thereof 上海应用技术大学 2022-06-10 CN disclosed
CN-107058453-A A kind of method of biocatalytic resolution lisinopril hydride 长兴制药股份有限公司 2017-08-18 CN disclosed
CN-106192061-A A kind of anophelifuge PBAT fiber 福建经纬新纤科技实业有限公司 2016-12-07 CN disclosed
CN-105294827-A Preparation method for enalapril maleate CHANGZHOU PHARMACEUTICAL FACTORY 2016-02-03 CN disclosed
EP-2481736-A1 Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases Deciphera Pharmaceuticals, LLC. (US) 2012-08-01 EP disclosed
EP-2148677-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2010-02-03 EP disclosed
US-20080269267-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-10-30 US disclosed
WO-2008131276-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFERATIVE DISEASES AND OTHER PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-10-30 WO disclosed
WO-1998001511-A1 REACTION PROCUCTS OF LYOTROPIC LIQUID CRYSTAL SALT COMPLEXES ELLIOTT STANLEY B (US) 1998-01-15 WO disclosed
US-4925969-A MICHAEL ADDITION, ALANINE OR LYSINE DERIVATIVE REACTED WITH ETHYL BENZOYLACRYLATE KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1990-05-15 US disclosed
EP-0190687-B1 PROCESS FOR PREPARING ETHYL-ALPHA-(1-CARBOXYETHYL)-AMINO-GAMMA-OXO-GAMMA-PHENYLBUTYRATE KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1988-10-05 EP disclosed
EP-0190687-A1 Process for preparing ethyl-alpha-(1-carboxyethyl)-amino-gamma-oxo-gamma-phenylbutyrate KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1986-08-13 EP disclosed
EP-0190687-A1 Process for preparing ethyl-alpha-(1-carboxyethyl)-amino-gamma-oxo-gamma-phenylbutyrate KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) 1986-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269267-A1 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF MYLEOPROLIFIC DISEASES AND OTHER PROLIFERATIVE DISEASES BRAF, RET, KIT CES2 2763/4885CES1 1692/4885CYP1A2 3494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.